



The Effects of Six Weeks High Intensity Interval Training on Amyloid Beta₁₋₄₂ Peptide in Hippocampus of Rat Model of Alzheimer's Disease Induced with STZ

Shokufeh Naderi ^{1,*}, Abdolhamid Habibi¹, Mahnaz Kesmati ², Anahita Rezaie³ and Mohsen Ghanbarzadeh¹

¹Department of Exercise Physiology, Shahid Chamran University of Ahvaz, Ahvaz, Iran

²Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

³Department of Pathobiology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran

*Corresponding author: Department of Exercise Physiology, Shahid Chamran University of Ahvaz, Ahvaz, Iran. Tel: +98-9197342452, Email: shokufehnaderi88@gmail.com

Received 2018 November 28; Revised 2018 December 09; Accepted 2018 December 10.

Abstract

Background: Alzheimer's disease is the formation of amyloid beta ($A\beta$) plaques and tau tangles in the brain. As $A\beta$ is an important factor in the pathogenesis of Alzheimer's disease, the present research aims to consider the effects of six weeks of high intensity interval training on $A\beta_{1-42}$ levels in the hippocampus tissue of male rat models of Alzheimer's disease.

Methods: Thirty-five rats (3 months old, 222.83 ± 19.60 g) were divided into five groups: Two experimental, two control and sham. Alzheimer's disease, induced by streptozotocin was infused into the rats i.c.v (a 3 mg/kg dose). Their memory was evaluated by passive avoidance learning method using a shuttle box. The amount of peptide $A\beta_{1-42}$ was measured by the ELISA method. Comparisons between groups were performed by One-way ANOVA followed by Tukey test. A value of $P < 0.05$ was considered to be significant.

Results: The $A\beta_{1-42}$ levels in the hippocampus of Alzheimer's control group was significantly higher than Alzheimer's HIIT group ($P = 0.036$) and it was lower in the health HIIT group than it was in the health control group ($P = 0.001$).

Conclusions: It declare that HIIT training lessen the level of $A\beta_{1-42}$ in the hippocampus and can be benefit for AD rat model. As a result, the advantages of HIIT training can be used in protection and treatment of AD.

Keywords: High Intensity Interval Training, Alzheimer's, Amyloid Beta, Hippocampus

1. Background

Alzheimer's is an age related disease and the chronic cause of dementia and degenerative brain especially in older adults' brain (1-3). Today, Alzheimer's is one of the most prevalent diseases of the nervous system (4). The two main factors in Alzheimer's are the formation of senile plaques composed of amyloid beta peptide ($A\beta$) and neurofibrillary tangles (NFT) composed of hyper phosphorylated protein tau (5). Amyloid beta, a monomer and a highly hydrophilic peptide. It has 37-49 amino acids which are generated by amyloid protein proteolysis (APP) (6, 7). The accumulation and precipitation of $A\beta_{1-42}$ as plaques in the brain is recognized as one of the main factors and primary phenomena in pathogenesis of Alzheimer's disease (8, 9). Studies indicate that injecting $A\beta$ into the hippocampus causes disorders in the learning ability and memory of rats and also leads to neurolysis and disorders in the performance of neurons (4).

Streptozotocin (STZ), as other N-nitroso compounds,

is an alkylating agent that causes tissue damage (10). A single 1-3 mg/kg injection of STZ causes atrophy and destroys nerve cells (11). Bilateral injections of 3 mg/kg of STZ lead to cognitive deficit, pathological plaques and phosphorylation of Tau (12, 13). STZ reduces brain metabolism and acetylcholine release and this plays an important role in reducing cognitive performance in Alzheimer's disease (14). Intracerebroventricular injection of STZ reduces metabolism by restraining the synthesis of adenosine triphosphate (ATP) and acetyl coenzyme A, consequently leading to cholinergic system impairment and reduction of acetyltransferase activity in the hippocampus; it enhances acetylcholinesterase activity in rat brain (14, 15). The increased expression of the tau protein in the hippocampus of ICV-STZ rat and some signs of $A\beta$ accumulation in the meningeal capillaries were found, indicating that the likelihood of the onset of Alzheimer's disease in this experimental model, thus giving further support to the resemblance of this experimental model to human

Alzheimer's disease (16). Some studies showed that exercise is a suitable non-pharmacological method for reducing the risks of Alzheimer's disease. They specified that exercise improves the memory and prevents its weakness in older adults (17).

Liu et al. showed that the number and size of $A\beta$ plaques in the hippocampus of transgenic rat model with AD (APP/PS1) reduced significantly at the intensity of 45% - 55% VO_2 max after 5 months of exercising on the treadmill. Also, $A\beta_{1-42}$ levels reduced significantly after exercising on the treadmill. Therefore, they suggested that exercise has an inhibitory effect on $A\beta$ levels (18). A study conducted by Yuede et al. showed that following 4 months of voluntary and forced running at low intensity (16 m/min) by transgenic rat model of AD (Tg2576), no significant differences were observed in $A\beta$ levels in brain cortex and hippocampus in the control and exercise groups (19). Um et al. also showed that running on the treadmill for 16 months at low intensity led to significant reductions in $A\beta_{1-42}$ protein levels in the brain of transgenic rat models of Alzheimer's group (NSE/APP sw) (20). Meanwhile, another study showed that a 3-week running exercise makes no changes in the levels of $A\beta$ in hippocampus of transgenic rat models of Alzheimer's disease (Tg2576) (21). Another study indicated that a 3-week running exercise at moderate intensity reduced soluble $A\beta_{1-40}$ and soluble fibrillary $A\beta$ in the cortex of Alzheimer's disease model rats (22). Furthermore, Bo et al. suggested that running on a treadmill at an intensity of 45% - 55% VO_2 max reduces $A\beta$ in the hippocampus of transgenic rat model of Alzheimer's disease (APP/PS1). They recommended that exercise can reduce $A\beta$ levels by improving mitochondrial function in the hippocampus and this should be considered as a therapy method for Alzheimer's disease (23).

However, endurance training is strongly recommended due its role in brain health. But one of the main reasons for not taking up such a training method is a lack of time in modern society (24). Creating a suitable, but shorter, exercise program with the characteristics of continuous endurance training is being considered by sports science experts. One of the training methods suggested by the experts of this field is high intensity interval training (HIIT), which is a powerful method for improving endurance performance with an advantage over traditional continuous endurance training in terms of saving time (25-27). Investigations have shown that doing these exercises for several weeks improves factors involved in metabolism such as maximum aerobic capacity, maximum activity of mitochondrial enzymes and mitochondrial biogenesis (28).

The question is asked whether HIIT can be as effective as traditional endurance training in keeping the brain healthy due to its shorter time period. Hence, here we used six weeks HIIT to survey amyloid beta₁₋₄₂ ($A\beta_{1-42}$) levels in

the Hippocampus of male Wistar rat models of Alzheimer's disease.

2. Methods

2.1. Animals

In this study, 35 twelve-weeks-old male Wistar rats were kept at temperatures of $22^\circ\text{C} \pm 2^\circ\text{C}$, light-dark cycle of 12:12 hours, and fed special feed for rats and water. All animals trained for 10 minutes a day for five days at speeds of 5 - 15 m/min to become familiar with the treadmill. Peak speed is calculated in order to determine maximum oxygen consumption using the Bedford et al. standard progressive test (29), which is standardized by Leandro et al. (30) for Wistar rats.

2.2. Experimental Design

Rats were randomly assigned into five groups (n = 7 per group): (1) control health, (2) control Alzheimer's, (3) HIIT health, (4) HIIT Alzheimer's and (5) sham. HIIT was performed 3 days a week, including warm up, the main training (interval reps) and cool down. Rats warmed up and cool down for 5 minutes on the treadmill at an intensity of 40% - 50% of peak speed. HIIT repetitions involved 2 minutes at an intensity of 80% - 110% maximum speed and low intensity interval repetitions included 2 minutes at an intensity of 30% - 40% maximum speed (Figure 1).

2.3. ICV Injection of STZ

The animals were anaesthetized with ketamine/xylazine (ratio of 6/60 mg/kg) i.p. and put on a stereotaxic (dual manipulator model 51600, USA). The skin was removed above the skull, and the coordinates for the lateral ventricles were measured using the Paxinos (31) atlas (anterioposterior -0.9 mm, lateral 5 mm, and dorsoventrally -3.2 mm). A burr hole was made in the skull with a hand drill. A 28-gauge Hamilton 10 μL syringe and piston attached to a microinjection unit was lowered manually through the hole into each lateral ventricle. The exercise and control groups were injected bilaterally with ICV-STZ (3 mg/kg, 5 μL). The sham group underwent the same surgical procedures, and the same STZ volume of saline was injected (32). After surgery, the rats were kept in a well-ventilated room at $25^\circ\text{C} \pm 2^\circ\text{C}$ in individual cages and had access to food and water ad libitum until they recovered full consciousness and then were housed together with three animals per cage.




Figure 1. Protocol outline for experimental procedures: The animals first 6-week exercise followed by icv stz injection. The behavior test was performed after 7 days. In the end, the animals were killed and their brains were kept at -80°C for laboratory tests).

2.4. Passive Avoidance Learning Test

The equipment for the passive avoidance task consisted of a light-dark box with 2 compartments ($18 \times 18 \times 25$ cm). A steel bar which can give an electric shock was installed on the floor of the dark compartment. The wall connecting the two compartments could be opened and shut like a guillotine. After leaving each experimental animal in the back compartment for one minute, they were placed in the front compartment for 10 seconds to adapt. In order to perform the transition test, a rat was placed in the lit compartment with its back to the restricted opening; 10 seconds later, the guillotine door was raised allowing the rat to enter the dark area before closing. After 1 minute, the rat was returned to the cage. Training started 24 hours after the transition test rat was placed in the lit chamber with its back to the guillotine door; the door was raised 10 seconds later. When the rat entered the dark compartment, the door closed and an electrical shock (75 V, 1.2 mA, 50 Hz) was delivered for 3 seconds. Then, the rat was taken out of the dark compartment and placed in the cage. In order to evaluate memory, 90 minutes and 24 hours after the electric shock, the rat was placed in the brightly lit compartment while the door between the two chambers was left open and delay time was recorded for the first entrance into the dark chamber. The latency to enter the dark compartment was measured up to a maximum of 300 seconds.

2.5. Sampling

After 10 days of I.C.V STZ, rats were sacrificed and their brains were taken out to dissect the hippocampus. The dissected brain parts were homogenized in 10 mM phosphate buffer (PB, pH 7.0) containing $10 \mu\text{L}/\text{mL}$ protease inhibitor to get 5% w/v homogenate. Collected hippocampus samples were kept at -80°C for consequent measurements. In order to measure $A\beta_{1-42}$ levels, first 50mg of hippocampus tissue was placed in a cold citrate-buffered saline. Then the tissue was homogenized for 10 minutes and centrifuged. The liquid was transferred into microtube. This solution

was used to measure $A\beta_{1-42}$ levels in the hippocampus tissue with ELISA kits from ZellBio GmbH (purchased from Padginteb Co, Tehran, Iran).

2.6. Statistical Analysis

Comparisons between groups were performed by One-way ANOVA followed by Tukey test. A value of $P < 0.05$ was considered to be significant. All statistical calculations were done using SPSS software version 22.

3. Results



The results of ANOVA indicated that there was a significant difference among groups for delay times in entering the dark compartment ($F_{4,25} = 23.755$, $P = 0.001$). Also, the Tukey post hoc test results showed that there were significant differences between the control health group and Alzheimer's group, and the HIIT health group and Alzheimer's group ($P < 0.001$) which indicates the validity of Alzheimer's model in the related groups (Figure 2). There were no significant differences between the control health group and the sham group ($P = 0.906$). Therefore, the sham group was set aside when investigating other variables and the remaining groups were compared with the control group only.

In Table 1, comparison of mean and standard deviation, as well as the findings of statistical test on the effects of HIIT on $A\beta_{1-42}$ levels in groups are given.

According to findings in Table 1, significant differences are observed in $A\beta_{1-42}$ levels among research groups ($F_{3,30} = 26.192$, $P = 0.001$). Furthermore, the Tukey post hoc test results showed that $A\beta_{1-42}$ levels were significantly higher in the control health group than in the HIIT group ($P = 0.001$) (Figure 3). Also, the $A\beta_{1-42}$ value was significantly lower in the HIIT Alzheimer's group than in the control Alzheimer's group ($P = 0.036$). $A\beta_{1-42}$ levels were higher in control Alzheimer's than control health group but this difference was not statistically significant ($P = 0.036$).

Table 1. Comparing $A\beta_{1-42}$ Levels in the Hippocampus Tissue of Research Groups and ANOVA Results

Group	Health Control	HIIT Health	Alzheimer's Control	Alzheimer's HIIT	F	P
$A\beta_{1-42}$ (ng/g tissue)	6.67 ± 1.18	3.66 ± 1.04	8.08 ± 0.46	6.55 ± 0.66	26.192	0.001

**Figure 2.** Comparison of delay time in groups**Figure 3.** $A\beta_{1-42}$ value in the hippocampus tissue of various groups

4. Discussion

It seems that this is the first research in which the protective effects of HIIT on $A\beta_{1-42}$ values in the hippocampus tissue of rat models of Alzheimer's disease are investigated. Results demonstrated that the injection of 3 mg of I.C.V STZ leads to significant increases of $A\beta_{1-42}$ in the hippocampus of rats (as the center of memory and learning). Changes in $A\beta_{1-42}$ levels due to HIIT may help reduce the progress of the disease and protect the brain against Alzheimer's. This disease is caused by the formation of aging plaques in the brain (33). Although this hypothesis has been reviewed in previous studies, Kang and Cho investigated the effects of a 6-week treadmill training (20 m/min) on insulin signaling and $A\beta_{1-42}$ levels in rat models of Alzheimer's by ICV-STZ injection. Their results showed significant $A\beta_{1-42}$ reductions and insulin signaling enhancements in the brain of training Alzheimer's rats compared to Alzheimer's control group (6). Therefore, the results of their study agree with the results of this research.

In the study by Yuede et al. following 16 weeks of voluntary and forced wheel running on the treadmill (same as the voluntary group), no significant differences were observed in soluble $A\beta$ levels ($A\beta_{42}$, $A\beta_{40}$) in the cortex and hippocampus tissue of the Tg2576 mouse model of Alzheimer's disease in the control and training groups (19). The results of this study do not agree with the current research. The mechanism of changes made by training on $A\beta_{1-42}$ are unknown, but the level of $A\beta_{1-42}$ present in the brain is a balance between its production, cleaning and destruction.

Results show that regular exercise weakens neuronal apoptosis involved in Alzheimer's disease pathogenesis by destroying or cleaning $A\beta$ deposits. It seems that HIIT, like continuous aerobic training, is effective in reducing $A\beta_{1-42}$ peptide in the hippocampus tissue of rats in Alzheimer's induced by STZ. Since HIIT exercise is advantageous in terms of time and work volume, it seems that such training may be used as a non-pharmacological therapeutic method for Alzheimer's disease in order to keep the nervous system healthy.

Acknowledgments

This article is extracted from the dissertation of Sport Physiology at Shahid Chamran University of Ahvaz.

Footnotes

Conflict of Interests: The authors have no conflict of interests.

Ethical Considerations: This study was approved by the Ethics Committee for Animal Experiments at Shahid Chamran University of Ahvaz.

Funding/Support: We would like to express our sincere gratitude to the Department of Sports and Youth of Khuzestan Province for their financial support.

References

- Iranmanesh F, Sayyadi A, Fayegh A, Shafiee Z. [Surveying of estrogen and progesterone effects on electroencephalogram and mini-mental status examination (MMSE) in female patients with Alzheimer's disease]. *J Birjand Univ Med Sci.* 2006;13(2):9-15. Persian.
- Siahmard Z, Alaei H, Reisi P, Pilehvarian AA. [Evaluation of the effects of red grape juice on Alzheimer's disease in rats]. *J Isfahan Med School.* 2012;29(167):2383-90. Persian.

3. Robinson MM, Lowe VJ, Nair KS. Increased brain glucose uptake after 12 weeks of aerobic high-intensity interval training in young and older adults. *J Clin Endocrinol Metabol*. 2017;**103**(1):221-7.
4. Souza LC, Carlos Filho B, Goes ATR, Del Fabbro L, de Gomes MG, Savegnago L, et al. Neuroprotective effect of physical exercise in a mouse model of Alzheimer's disease induced by β -amyloid1-40 peptide. *Neurotox Res*. 2013;**24**(2):148-63.
5. Lopez-Camacho PY, Guzman-Hernandez R, Hernandez Gonzalez VH, Diaz Munoz JE, Garcia-Sierra F, Basurto-Islas G. [Research and therapeutics in Alzheimer's disease based on amyloid beta and tau]. *Neurosci Arch*. 2018;**22**(2):72-88. Spanish.
6. Kang EB, Cho JY. Effects of treadmill exercise on brain insulin signaling and beta-amyloid in intracerebroventricular streptozotocin induced-memory impairment in rats. *J Exerc Nutrition Biochem*. 2014;**18**(1):89-96. doi: [10.5717/jenb.2014.18.1.89](https://doi.org/10.5717/jenb.2014.18.1.89). [PubMed: [25566443](https://pubmed.ncbi.nlm.nih.gov/25566443/)]. [PubMed Central: [PMC4241930](https://pubmed.ncbi.nlm.nih.gov/PMC4241930/)].
7. Qiang W, Yau WM, Lu JX, Collinge J, Tycko R. Structural variation in amyloid-beta fibrils from Alzheimer's disease clinical subtypes. *Nature*. 2017;**541**(7636):217-21. doi: [10.1038/nature20814](https://doi.org/10.1038/nature20814). [PubMed: [28052060](https://pubmed.ncbi.nlm.nih.gov/28052060/)]. [PubMed Central: [PMC5233555](https://pubmed.ncbi.nlm.nih.gov/PMC5233555/)].
8. Kumar A, Singh A; Ekavali. A review on Alzheimer's disease pathophysiology and its management: An update. *Pharmacol Rep*. 2015;**67**(2):195-203. doi: [10.1016/j.pharep.2014.09.004](https://doi.org/10.1016/j.pharep.2014.09.004). [PubMed: [25712639](https://pubmed.ncbi.nlm.nih.gov/25712639/)].
9. Podolski IY, Podlubnaya ZA, Kosenko EA, Mugantseva EA, Makarova EG, Marsagishvili LG, et al. Effects of hydrated forms of C60 fullerene on amyloid β -Peptide fibrillization in vitro and performance of the cognitive task. *J Nanosci Nanotechnol*. 2007;**7**(4-5):1479-85. doi: [10.1166/jnn.2007.330](https://doi.org/10.1166/jnn.2007.330). [PubMed: [17450915](https://pubmed.ncbi.nlm.nih.gov/17450915/)].
10. Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. *J Am Geriatr Soc*. 1997;**45**(6):718-24. [PubMed: [9180666](https://pubmed.ncbi.nlm.nih.gov/9180666/)].
11. Kraska A, Santin MD, Dorieux O, Joseph-Mathurin N, Bourrin E, Petit F, et al. In vivo cross-sectional characterization of cerebral alterations induced by intracerebroventricular administration of streptozotocin. *PLoS ONE*. 2012;**7**(9). e46196. doi: [10.1371/journal.pone.0046196](https://doi.org/10.1371/journal.pone.0046196). [PubMed: [23049978](https://pubmed.ncbi.nlm.nih.gov/23049978/)]. [PubMed Central: [PMC3458017](https://pubmed.ncbi.nlm.nih.gov/PMC3458017/)].
12. Devi L, Allred MJ, Ginsberg SD, Ohno M. Mechanisms underlying insulin deficiency-induced acceleration of β -amyloidosis in a mouse model of alzheimer's disease. *PLoS ONE*. 2012;**7**(3). e32792. doi: [10.1371/journal.pone.0032792](https://doi.org/10.1371/journal.pone.0032792). [PubMed: [22403710](https://pubmed.ncbi.nlm.nih.gov/22403710/)]. [PubMed Central: [PMC3293895](https://pubmed.ncbi.nlm.nih.gov/PMC3293895/)].
13. Jolivald CG, Hurford R, Lee CA, Dumaop W, Rockenstein E, Masliah E. Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice. *Exp Neurol*. 2010;**223**(2):422-31. doi: [10.1016/j.expneurol.2009.11.005](https://doi.org/10.1016/j.expneurol.2009.11.005). [PubMed: [19931251](https://pubmed.ncbi.nlm.nih.gov/19931251/)]. [PubMed Central: [PMC2864332](https://pubmed.ncbi.nlm.nih.gov/PMC2864332/)].
14. Jahangiri L, Kesmati M, Najafzadeh H. Evaluation of analgesic and anti-inflammatory effect of nanoparticles of magnesium oxide in mice with and without ketamine. *Eur Rev Med Pharmacol Sci*. 2013;**17**(20):2706-10. [PubMed: [24174350](https://pubmed.ncbi.nlm.nih.gov/24174350/)].
15. Bassani TB, Bonato JM, Machado MMF, C oppola-Segovia V, Moura ELR, Zanata SM, et al. Decrease in adult neurogenesis and neuroinflammation are involved in spatial memory impairment in the streptozotocin-induced model of sporadic Alzheimer's disease in rats. *Molec Neurobiol*. 2018;**55**(5):4280-96. doi: [10.1007/s12035-017-0645-9](https://doi.org/10.1007/s12035-017-0645-9). [PubMed: [28623617](https://pubmed.ncbi.nlm.nih.gov/28623617/)].
16. Grunblatt E, Koutsilieris E, Hoyer S, Riederer P. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. *J Alzheimer Dis*. 2006;**9**(3):261-71. doi: [10.3233/jad-2006-9305](https://doi.org/10.3233/jad-2006-9305). [PubMed: [16914836](https://pubmed.ncbi.nlm.nih.gov/16914836/)].
17. Kramer AF, Erickson KI, Colcombe SJ. Exercise, cognition, and the aging brain. *J Appl Physiol* (1985). 2006;**101**(4):1237-42. doi: [10.1152/jap-physiol.00500.2006](https://doi.org/10.1152/jap-physiol.00500.2006). [PubMed: [16778001](https://pubmed.ncbi.nlm.nih.gov/16778001/)].
18. Liu HL, Zhao G, Zhang H, Shi LD. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice. *Behav Brain Res*. 2013;**256**:261-72. doi: [10.1016/j.bbr.2013.08.008](https://doi.org/10.1016/j.bbr.2013.08.008). [PubMed: [23968591](https://pubmed.ncbi.nlm.nih.gov/23968591/)].
19. Yuede CM, Zimmerman SD, Dong H, Kling MJ, Bero AW, Holtzman DM, et al. Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease. *Neurobiol Dis*. 2009;**35**(3):426-32. doi: [10.1016/j.nbd.2009.06.002](https://doi.org/10.1016/j.nbd.2009.06.002). [PubMed: [19524672](https://pubmed.ncbi.nlm.nih.gov/19524672/)]. [PubMed Central: [PMC2745233](https://pubmed.ncbi.nlm.nih.gov/PMC2745233/)].
20. Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, et al. Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. *Inter J Molec Med*. 2008;**22**(4):529-39. [PubMed: [18813861](https://pubmed.ncbi.nlm.nih.gov/18813861/)].
21. Parachikova A, Nichol KE, Cotman CW. Short-term exercise in aged Tg2576 mice alters neuroinflammation and improves cognition. *Neurobiol Dis*. 2008;**30**(1):121-9. doi: [10.1016/j.nbd.2007.12.008](https://doi.org/10.1016/j.nbd.2007.12.008). [PubMed: [18258444](https://pubmed.ncbi.nlm.nih.gov/18258444/)]. [PubMed Central: [PMC2386749](https://pubmed.ncbi.nlm.nih.gov/PMC2386749/)].
22. Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, Cotman CW. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. *J Neuroinflammation*. 2008;**5**:13. doi: [10.1186/1742-2094-5-13](https://doi.org/10.1186/1742-2094-5-13). [PubMed: [18400101](https://pubmed.ncbi.nlm.nih.gov/18400101/)]. [PubMed Central: [PMC2329612](https://pubmed.ncbi.nlm.nih.gov/PMC2329612/)].
23. Bo H, Kang W, Jiang N, Wang X, Zhang Y, Ji LL. Exercise-induced neuroprotection of hippocampus in APP/PS1 transgenic mice via upregulation of mitochondrial 8-oxoguanine DNA glycosylase. *Oxid Med Cell Longev*. 2014;**2014**:834502. doi: [10.1155/2014/834502](https://doi.org/10.1155/2014/834502). [PubMed: [25538817](https://pubmed.ncbi.nlm.nih.gov/25538817/)]. [PubMed Central: [PMC4236906](https://pubmed.ncbi.nlm.nih.gov/PMC4236906/)].
24. Godin G, Desharnais R, Valois P, Lepage L, Jobin J, Bradet R. Differences in perceived barriers to exercise between high and low intenders: Observations among different populations. *Am J Health Promot*. 2016;**8**(4):279-85. doi: [10.4278/0890-1171-8.4.279](https://doi.org/10.4278/0890-1171-8.4.279).
25. Gibala MJ, Little JP, van Essen M, Wilkin GP, Burgomaster KA, Safdar A, et al. Short-term sprint interval versus traditional endurance training: Similar initial adaptations in human skeletal muscle and exercise performance. *J Physiol*. 2006;**575**(Pt 3):901-11. doi: [10.1113/jphysiol.2006.112094](https://doi.org/10.1113/jphysiol.2006.112094). [PubMed: [16825308](https://pubmed.ncbi.nlm.nih.gov/16825308/)]. [PubMed Central: [PMC1995688](https://pubmed.ncbi.nlm.nih.gov/PMC1995688/)].
26. Schmitz B, Nelis P, Rolles F, Alnawaiseh M, Klose A, Kruger M, et al. Effects of high-intensity interval training on optic nerve head and macular perfusion using optical coherence tomography angiography in healthy adults. *Atherosclerosis*. 2018;**274**:8-15. doi: [10.1016/j.atherosclerosis.2018.04.028](https://doi.org/10.1016/j.atherosclerosis.2018.04.028). [PubMed: [29747089](https://pubmed.ncbi.nlm.nih.gov/29747089/)].
27. Lamb SE, Sheehan B, Atherton N, Nichols V, Collins H, Mistry D, et al. Dementia and physical activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: Randomised controlled trial. *BMJ*. 2018;**361**:k1675. doi: [10.1136/bmj.k1675](https://doi.org/10.1136/bmj.k1675). [PubMed: [29769247](https://pubmed.ncbi.nlm.nih.gov/29769247/)]. [PubMed Central: [PMC5953238](https://pubmed.ncbi.nlm.nih.gov/PMC5953238/)].
28. Gibala MJ, Little JP, Macdonald MJ, Hawley JA. Physiological adaptations to low-volume, high-intensity interval training in health and disease. *J Physiol*. 2012;**590**(5):1077-84. doi: [10.1113/jphysiol.2011.224725](https://doi.org/10.1113/jphysiol.2011.224725). [PubMed: [22289907](https://pubmed.ncbi.nlm.nih.gov/22289907/)]. [PubMed Central: [PMC3381816](https://pubmed.ncbi.nlm.nih.gov/PMC3381816/)].
29. Bedford TG, Tipton CM, Wilson NC, Oppliger RA, Gisolfi CV. Maximum oxygen consumption of rats and its changes with various experimental procedures. *J Appl Physiol Respir Environ Exerc Physiol*. 1979;**47**(6):1278-83. doi: [10.1152/jappl.1979.47.6.1278](https://doi.org/10.1152/jappl.1979.47.6.1278). [PubMed: [536299](https://pubmed.ncbi.nlm.nih.gov/536299/)].
30. Leandro CG, Levada AC, Hirabara SM, Manhaes-de-Castro R, De-Castro CB, Curi R, et al. A program of moderate physical training for Wistar rats based on maximal oxygen consumption. *J Strength Cond Res*. 2007;**21**(3):751-6. doi: [10.1519/R-2015.1](https://doi.org/10.1519/R-2015.1). [PubMed: [17685693](https://pubmed.ncbi.nlm.nih.gov/17685693/)].
31. Paxinos GAWC, Watson C. *The rat brain atlas in stereotaxic coordinates*. 3rd ed. San Diego: Academic Press; 1997.
32. Rupinder KS, Nirmal S. All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer's type. *Prog Neuropsychopharmacol Biol Psychiatry*. 2013;**40**:38-46. doi: [10.1016/j.pnpbp.2012.09.012](https://doi.org/10.1016/j.pnpbp.2012.09.012). [PubMed: [23044340](https://pubmed.ncbi.nlm.nih.gov/23044340/)].
33. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science*. 2002;**297**(5580):353-6. doi: [10.1126/science.1072994](https://doi.org/10.1126/science.1072994). [PubMed: [12130773](https://pubmed.ncbi.nlm.nih.gov/12130773/)].